SeaStar Medical Sets Sights on Expanding Treatment Options for Critical Conditions
SeaStar Medical, a leading biotechnology company focused on developing innovative treatments for ultra-rare and critical conditions, has announced its impressive achievements in the fourth quarter of 2025. In a recent conference call, Eric Schlorff, Chief Executive Officer, highlighted the company's progress in expanding the use of QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI), as well as advancing the development of SCD therapy as a potential treatment for adult patients with AKI.
According to Schlorff, SeaStar Medical added 13 new customers from top-rated children's hospitals, bringing the total customer base to 16 and building increased depth in customer orders. The company also reported net revenue of over $1 million from QUELIMMUNE sales in 2025, with pharma-like gross profit margins above 90%. Furthermore, SeaStar Medical advanced the development of SCD therapy as a potential treatment for adult patients with AKI, achieving over 50% enrollment in the NEUTRALIZE-AKI pivotal trial.
SeaStar Medical has also initiated a modular pre-market application (PMA) submission process for the SCD therapy as a potential treatment for the adult AKI indication. The company has been granted Breakthrough Device Designation by the FDA for this indication, which is expected to speed up the PMA approval process.
Looking ahead to 2026, SeaStar Medical has laid out four key milestones to drive stakeholder value and position itself solidly for 2027 and beyond. The company's primary goal this year is to advance the SCD therapy for the adult AKI indication, with plans to complete enrollment in the NEUTRALIZE-AKI pivotal trial around the end of 2026.
Additionally, SeaStar Medical aims to further expand its customer base in 2026 through QUELIMMUNE sales. The company has strong momentum in the pediatric market, with the publication of its SAVE registry data in Pediatric Nephrology and strong testimonials from existing customers. SeaStar Medical plans to add 15 new top-ranked children's medical centers this year, with a goal of achieving $2 million product revenue from QUELIMMUNE sales in 2026.
The company also announced the initiation of a clinical trial of the SCD therapy in patients with acute congestive heart failure with cardiorenal syndrome awaiting left ventricular assist device implantation. This trial is investigator-led and being funded by the NIH, highlighting SeaStar Medical's commitment to exploring new treatment options for critical conditions.
SeaStar Medical has also expressed its intention to work with the FDA for expedited approval of its pipeline indications. The Humanitarian Use and Breakthrough Device designations would enable the company to potentially provide earlier access to patients with destructive hyperinflammatory conditions that face permanent organ failure or loss of life.
